JP2019531084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531084A5 JP2019531084A5 JP2019521178A JP2019521178A JP2019531084A5 JP 2019531084 A5 JP2019531084 A5 JP 2019531084A5 JP 2019521178 A JP2019521178 A JP 2019521178A JP 2019521178 A JP2019521178 A JP 2019521178A JP 2019531084 A5 JP2019531084 A5 JP 2019531084A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- chain variable
- variable region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 44
- 210000004027 cell Anatomy 0.000 claims 40
- 239000000427 antigen Substances 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 102000036639 antigens Human genes 0.000 claims 33
- 230000027455 binding Effects 0.000 claims 30
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 27
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 102000002029 Claudin Human genes 0.000 claims 13
- 108050009302 Claudin Proteins 0.000 claims 13
- 210000002865 immune cell Anatomy 0.000 claims 12
- 101000685724 Homo sapiens Protein S100-A4 Proteins 0.000 claims 10
- 102100023087 Protein S100-A4 Human genes 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 5
- 102000002227 Interferon Type I Human genes 0.000 claims 5
- 108010014726 Interferon Type I Proteins 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 201000004101 esophageal cancer Diseases 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 206010017758 gastric cancer Diseases 0.000 claims 5
- 201000005202 lung cancer Diseases 0.000 claims 5
- 208000020816 lung neoplasm Diseases 0.000 claims 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 201000002528 pancreatic cancer Diseases 0.000 claims 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 5
- 201000011549 stomach cancer Diseases 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 229940075993 receptor modulator Drugs 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 230000009871 nonspecific binding Effects 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002458 cell surface marker Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610536449.9 | 2016-07-08 | ||
| CN201610536449 | 2016-07-08 | ||
| PCT/CN2017/082024 WO2017186121A1 (zh) | 2016-04-26 | 2017-04-26 | 一种改善免疫应答细胞功能的方法 |
| CNPCT/CN2017/082024 | 2017-04-26 | ||
| PCT/CN2017/092381 WO2018006882A1 (zh) | 2016-07-08 | 2017-07-10 | 抗密蛋白18a2的抗体及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531084A JP2019531084A (ja) | 2019-10-31 |
| JP2019531084A5 true JP2019531084A5 (OSRAM) | 2020-09-03 |
| JP7587921B2 JP7587921B2 (ja) | 2024-11-21 |
Family
ID=60912336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521178A Active JP7587921B2 (ja) | 2016-07-08 | 2017-07-10 | 抗クローディンタンパク質１８ａ２の抗体及びその応用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11111295B2 (OSRAM) |
| EP (1) | EP3483182B1 (OSRAM) |
| JP (1) | JP7587921B2 (OSRAM) |
| KR (1) | KR102723896B1 (OSRAM) |
| CN (1) | CN109790222B (OSRAM) |
| AU (1) | AU2017294276B2 (OSRAM) |
| BR (1) | BR112019000327A8 (OSRAM) |
| CA (1) | CA3030257A1 (OSRAM) |
| CL (1) | CL2019000061A1 (OSRAM) |
| ES (1) | ES2979068T3 (OSRAM) |
| IL (1) | IL264144B2 (OSRAM) |
| SG (1) | SG11201900171QA (OSRAM) |
| WO (1) | WO2018006882A1 (OSRAM) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018006882A1 (zh) * | 2016-07-08 | 2018-01-11 | 科济生物医药（上海）有限公司 | 抗密蛋白18a2的抗体及其应用 |
| WO2019149279A1 (zh) | 2018-02-02 | 2019-08-08 | 科济生物医药（上海）有限公司 | 细胞免疫治疗的组合 |
| BR112020015479A2 (pt) * | 2018-03-08 | 2020-12-08 | Phanes Therapeutics, Inc. | Anticorpos anticlaudina 18.2 e usos dos mesmos |
| CN111989344A (zh) * | 2018-03-09 | 2020-11-24 | 科济生物医药（上海）有限公司 | 用于治疗肿瘤的方法和组合物 |
| KR20200130831A (ko) * | 2018-03-14 | 2020-11-20 | 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 | 항-클라우딘 18.2 항체 |
| WO2019210863A1 (zh) | 2018-05-03 | 2019-11-07 | 科济生物医药（上海）有限公司 | 免疫效应细胞及其应用 |
| WO2019219029A1 (zh) | 2018-05-15 | 2019-11-21 | 科济生物医药（上海）有限公司 | 基因工程化的细胞及应用 |
| CN116178555B (zh) | 2018-05-18 | 2025-09-09 | 礼新医药科技(上海)有限公司 | 抗密蛋白18.2抗体及其用途 |
| CN112930199B (zh) | 2018-07-24 | 2024-08-13 | 恺兴生命科技(上海)有限公司 | 免疫效应细胞治疗肿瘤的方法 |
| CN118955712A (zh) * | 2018-07-25 | 2024-11-15 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| CN110857322A (zh) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
| CA3110593A1 (en) * | 2018-08-27 | 2020-03-05 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-claudin18.2 antibody and use thereof |
| CN109206524B (zh) * | 2018-09-25 | 2022-04-05 | 山东兴瑞生物科技有限公司 | 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途 |
| US20220033491A1 (en) * | 2018-09-30 | 2022-02-03 | Cafa Therapeutics Limited | Combination therapy of cldn18 antibody and chemotherapy drugs |
| CN113164408B (zh) | 2018-12-07 | 2025-07-22 | 克莱格医学有限公司 | 肿瘤联合免疫治疗 |
| EP3891183A4 (en) * | 2018-12-07 | 2022-08-31 | Zlip Holding Limited | ANTI-CLAUDIN ANTIBODIES AND USES THEREOF |
| BR112021012608A2 (pt) | 2018-12-28 | 2021-09-08 | Nanjing GenScript Biotech Co., Ltd. | Porção de ligação que se liga especificamente à claudina18.2, receptor de antígeno quimérico, ácido nucleico, célula imune manipulada, composição farmacêutica, e, método de tratamento de um tumor ou câncer que expressa claudina18.2 |
| CN113166246B (zh) * | 2018-12-28 | 2024-10-18 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
| EP3909590A4 (en) | 2019-01-07 | 2022-11-16 | CRAGE medical Co., Limited | ASSOCIATION FOR CELLULAR IMMUNOTHERAPY |
| CN111434692B (zh) * | 2019-01-15 | 2021-12-31 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| US11407828B2 (en) | 2019-02-01 | 2022-08-09 | Novarock Biotherapeutics, Ltd. | Anti-CLauDiN 18 antibodies and methods of use thereof |
| JP2022523749A (ja) * | 2019-02-01 | 2022-04-26 | クレージュ メディカル カンパニー，リミテッド | Ｔｃｒ融合タンパク質およびｔｃｒ融合タンパク質を発現する細胞 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| TW202042824A (zh) * | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-MUC1嵌合抗原受體（CAR）T細胞療法 |
| JP2022527173A (ja) * | 2019-03-29 | 2022-05-31 | フェインズ セラピューティクス，インコーポレーテッド | ヒト化抗クローディン１８．２キメラ抗原受容体及びその使用 |
| US12428478B2 (en) * | 2019-04-01 | 2025-09-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-Claudin 18.2 antibody and application thereof |
| CN113748133B (zh) * | 2019-04-19 | 2024-07-02 | 康诺亚生物医药科技（成都）有限公司 | 肿瘤治疗剂及其应用 |
| AU2020273695B2 (en) | 2019-05-16 | 2024-10-31 | Qilu Pharmaceutical Co., Ltd. | Antibody against claudin 18A2 and use thereof |
| CN114206935B (zh) * | 2019-05-24 | 2024-01-12 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
| CN111978402B (zh) * | 2019-05-24 | 2022-06-28 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
| JP7266117B2 (ja) * | 2019-05-30 | 2023-04-27 | 山東博安生物技術股▲ふん▼有限公司 | クローディン１８．２を標的とする抗体又はキメラ抗原受容体 |
| KR20250044762A (ko) * | 2019-07-17 | 2025-04-01 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Claudin18 항체 및 암 치료 방법 |
| AU2020329466B2 (en) * | 2019-08-12 | 2024-08-01 | Abl Bio Inc. | Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof |
| CN112574307B (zh) | 2019-09-29 | 2023-11-28 | 迈威(上海)生物科技股份有限公司 | 抗人Claudin18.2抗体及其应用 |
| MX2022005452A (es) | 2019-11-05 | 2022-07-27 | Lanova Medicines Ltd | Conjugados farmaco-anticuerpo dirigidos a la claudina 18.2. |
| WO2021104511A1 (zh) * | 2019-11-29 | 2021-06-03 | 苏州诺沃泰医药科技有限公司 | Cart细胞在制备治疗癌症的药物中的应用 |
| AU2020398045A1 (en) | 2019-12-06 | 2022-06-09 | Sotio Biotech A.S. | Humanized CLDN18.2 antibodies |
| BR112022012327A2 (pt) | 2019-12-23 | 2022-10-18 | Sotio Biotech A S | Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira |
| JP7543411B2 (ja) * | 2020-01-03 | 2024-09-02 | クレージュ メディカル カンパニー，リミテッド | 抗クロ―ディン１８．２の抗体及びその使用 |
| KR20220140786A (ko) * | 2020-02-10 | 2022-10-18 | 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 | 클라우딘18.2 항체 및 그것의 사용 |
| EP4110820A4 (en) * | 2020-02-25 | 2024-03-27 | Gensun Biopharma Inc. | TRISPECIFIC T CELL CONTACTING AGENTS |
| JP7407973B2 (ja) * | 2020-05-15 | 2024-01-04 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗体薬物複合体、その調製方法、およびその使用 |
| WO2021254481A1 (zh) * | 2020-06-19 | 2021-12-23 | 信达生物制药(苏州)有限公司 | 抗Claudin18.2抗体以及其用途 |
| CN111704669B (zh) * | 2020-07-13 | 2022-05-13 | 北京凯因科技股份有限公司 | 一种用于治疗晚期胃癌的抗cldn18全人源化抗体 |
| CN113929780A (zh) * | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| CN111961135B (zh) * | 2020-07-13 | 2022-08-16 | 北京亦庄国际蛋白药物技术有限公司 | 一种用于预防或治疗癌症的抗体 |
| CN114222761B (zh) * | 2020-07-14 | 2024-02-20 | 浙江道尔生物科技有限公司 | 一种抗cld18a2的单域抗体 |
| WO2022028623A1 (zh) | 2020-08-07 | 2022-02-10 | 佧珐药业有限公司 | 工程化改造的细胞以及工程化改造细胞的方法 |
| EP4222174A4 (en) * | 2020-09-30 | 2025-02-12 | Nanjing GenScript Biotech Co., Ltd. | Antibodies targeting human claudin 18.2 and uses thereof |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス，インコーポレイテッド | プロテアーゼ活性化ｃｄ４５ゲートｃａｒ |
| AU2021405049A1 (en) | 2020-12-23 | 2023-06-22 | Sotio Biotech A.S. | Tumor-specific claudin 18.2 antibody-drug conjugates |
| KR20230142470A (ko) | 2021-01-29 | 2023-10-11 | 알로젠 테라퓨틱스 인코포레이티드 | 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃 |
| WO2022214089A1 (zh) | 2021-04-08 | 2022-10-13 | 克莱格医学有限公司 | 细胞免疫治疗的应用 |
| WO2022218375A1 (zh) * | 2021-04-15 | 2022-10-20 | 克莱格医学有限公司 | 嵌合t细胞受体及其应用 |
| US20250269028A1 (en) | 2021-06-29 | 2025-08-28 | Carsgen Therapeutics Co., Ltd | Chimeric polypeptide for regulating cell physiological activity |
| CN115057930B (zh) * | 2021-09-03 | 2022-11-29 | 深圳市先康达生命科学有限公司 | 靶向人Claudin18.2蛋白的单克隆抗体及其应用 |
| EP4428154A1 (en) * | 2021-11-05 | 2024-09-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anti-cldn18.2 antibody and use thereof |
| CN119677781A (zh) * | 2022-05-06 | 2025-03-21 | 上海先博生物科技有限公司 | 靶向cldn18.2的嵌合抗原t细胞受体及其应用 |
| WO2024022495A1 (en) * | 2022-07-28 | 2024-02-01 | Concept To Medicine Biotech Co., Ltd. | Anti-MerTK ANTIBODIES AND USES THEREOF |
| US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| WO2025026347A1 (en) * | 2023-07-31 | 2025-02-06 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and methods of use thereof |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| CN117430708B (zh) * | 2023-12-21 | 2024-04-09 | 苏州近岸蛋白质科技股份有限公司 | 一种抗Claudin18.2抗体 |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN120005046B (zh) * | 2025-04-18 | 2025-09-02 | 深锐(天津)生物医学有限公司 | 双靶点嵌合抗原受体联合pd-1与il-21融合蛋白 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN120137056A (zh) * | 2014-07-17 | 2025-06-13 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| AU2016364853A1 (en) | 2015-12-04 | 2018-06-21 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
| WO2017186121A1 (zh) * | 2016-04-26 | 2017-11-02 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| WO2018006882A1 (zh) * | 2016-07-08 | 2018-01-11 | 科济生物医药（上海）有限公司 | 抗密蛋白18a2的抗体及其应用 |
| CN111989344A (zh) * | 2018-03-09 | 2020-11-24 | 科济生物医药（上海）有限公司 | 用于治疗肿瘤的方法和组合物 |
| US20220033491A1 (en) * | 2018-09-30 | 2022-02-03 | Cafa Therapeutics Limited | Combination therapy of cldn18 antibody and chemotherapy drugs |
| EP3909590A4 (en) * | 2019-01-07 | 2022-11-16 | CRAGE medical Co., Limited | ASSOCIATION FOR CELLULAR IMMUNOTHERAPY |
| WO2022033483A1 (zh) * | 2020-08-10 | 2022-02-17 | 佧珐药业有限公司 | 多功能的免疫效应细胞及其应用 |
-
2017
- 2017-07-10 WO PCT/CN2017/092381 patent/WO2018006882A1/zh not_active Ceased
- 2017-07-10 KR KR1020197003874A patent/KR102723896B1/ko active Active
- 2017-07-10 AU AU2017294276A patent/AU2017294276B2/en active Active
- 2017-07-10 BR BR112019000327A patent/BR112019000327A8/pt unknown
- 2017-07-10 CN CN201780042611.4A patent/CN109790222B/zh active Active
- 2017-07-10 SG SG11201900171QA patent/SG11201900171QA/en unknown
- 2017-07-10 US US16/316,331 patent/US11111295B2/en active Active
- 2017-07-10 JP JP2019521178A patent/JP7587921B2/ja active Active
- 2017-07-10 IL IL264144A patent/IL264144B2/en unknown
- 2017-07-10 EP EP17823694.9A patent/EP3483182B1/en active Active
- 2017-07-10 ES ES17823694T patent/ES2979068T3/es active Active
- 2017-07-10 CA CA3030257A patent/CA3030257A1/en active Pending
-
2019
- 2019-01-08 CL CL2019000061A patent/CL2019000061A1/es unknown
-
2021
- 2021-08-05 US US17/395,223 patent/US20220185880A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531084A5 (OSRAM) | ||
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| JP2020510422A5 (OSRAM) | ||
| JP2017519759A5 (OSRAM) | ||
| JP2022093564A5 (OSRAM) | ||
| JP2020501531A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| JP2019532625A5 (OSRAM) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2018527919A5 (OSRAM) | ||
| JP2013527762A5 (OSRAM) | ||
| JP2018529327A5 (OSRAM) | ||
| JP2018506961A5 (OSRAM) | ||
| JP2013506428A5 (OSRAM) | ||
| IL295295A (en) | Antibodies against fcrl5 and methods of their use | |
| JP2013527761A5 (OSRAM) | ||
| JP2014522850A5 (OSRAM) | ||
| JP2020529835A5 (OSRAM) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2010535713A5 (OSRAM) | ||
| JP2017526339A5 (OSRAM) | ||
| JP2019512207A5 (OSRAM) | ||
| JP2013519364A5 (OSRAM) | ||
| RU2018122629A (ru) | Антитела против 5t4 и конъюгаты антитело-лекарственное средство | |
| JP2020534012A5 (OSRAM) |